Immunomodulatory effects of glatiramer acetate as they relate to stage-specific immune dysregulation in multiple sclerosis.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1254/fpj.148.105PMID 27478050
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The role of immune cells, glia and neurons in white and gray matter pathology in multiple sclerosis.

  2015cited by this paper
• Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial.

  2015cited by this paper
• IgE-Mediated Allergic Reactions after the First Administration of Glatiramer Acetate in Patients with Multiple Sclerosis

  2015cited by this paper
• Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort.

  2015cited by this paper
• The Effect of Disease Modifying Therapies on Brain Atrophy in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis

  2015cited by this paper
• The Effect of Disease Modifying Therapies on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis

  2015cited by this paper
• Glatiramer acetate: long-term safety and efficacy in relapsing-remitting multiple sclerosis

  2015cited by this paper
• Can we switch microglia's phenotype to foster neuroprotection? Focus on multiple sclerosis

  2014cited by this paper
• Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.

  2014cited by this paper
• The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment.

  2014cited by this paper
• Comparing the Biological Impact of Glatiramer Acetate with the Biological Impact of a Generic

  2014cited by this paper
• A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial

  2014cited by this paper
• Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis

  2014cited by this paper
• Stage-Specific Immune Dysregulation in Multiple Sclerosis

  2014cited by this paper
• A unified cell biological perspective on axon–myelin injury

  2014cited by this paper
• Relating relapse and T2 lesion changes to disability progression in multiple sclerosis: a systematic literature review and regression analysis

  2013cited by this paper
• Randomized study combining interferon and glatiramer acetate in multiple sclerosis

  2013cited by this paper
• Multiple sclerosis and pregnancy: therapeutic considerations

  2013cited by this paper
• Multiple sclerosis: Prospects and promise

  2013cited by this paper
• Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome

  2013cited by this paper
• Glatiramer Acetate in Treatment of Multiple Sclerosis: A Toolbox of Random Co-Polymers for Targeting Inflammatory Mechanisms of both the Innate and Adaptive Immune System?

  2012cited by this paper
• Glatiramer acetate for treatment of relapsing–remitting multiple sclerosis

  2012cited by this paper
• Maintenance plasma exchange therapy for steroid‐refractory neuromyelitis optica

  2012cited by this paper
• Injectable multiple sclerosis medications: a patient survey of factors associated with injection-site reactions.

  2012cited by this paper
• Interferon β-1b and glatiramer acetate effects on permanent black hole evolution

  2011cited by this paper
• Glatiramer acetate (GA, Copolymer-1) an hypothetical treatment option for Rett syndrome.

  2011cited by this paper
• Glatiramer Acetate in the Treatment of Multiple Sclerosis

  2011cited by this paper
• Interferon-β but not Glatiramer acetate stimulates CXCL10 secretion in primary cultures of thyrocytes: a clue for understanding the different risks of thyroid dysfunctions in patients with multiple sclerosis treated with either of the two drugs.

  2011cited by this paper
• Glatiramer Acetate Modulates TNF-α and IL-10 Secretion in Microglia and Promotes Their Phagocytic Activity

  2011cited by this paper
• Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis

  2010cited by this paper
• Effect of Oral Antihistamine on Local Injection Site Reactions With Self-Administered Glatiramer Acetate

  2010cited by this paper
• Tolerability and safety of novel half milliliter formulation of glatiramer acetate for subcutaneous injection: an open-label, multicenter, randomized comparative study

  2010cited by this paper
• Freedom from disease activity in multiple sclerosis

  2010cited by this paper
• New acute and chronic black holes in patients with multiple sclerosis randomised to interferon beta-1b or glatiramer acetate

  2009cited by this paper
• GLANCE

  2009cited by this paper
• Induction of CD4+CD25+Foxp3+ regulatory T cell response by glatiramer acetate in type 1 diabetes

  2009cited by this paper
• 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.

  2009cited by this paper
• The challenge of multiple sclerosis: How do we cure a chronic heterogeneous disease?

  2009cited by this paper
• Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial.

  2009cited by this paper
• Antibody to aquaporin-4 in the long-term course of neuromyelitis optica

  2008cited by this paper
• Demyelination arrest and remyelination induced by glatiramer acetate treatment of experimental autoimmune encephalomyelitis

  2008cited by this paper
• Glatiramer Acetate

  2008cited by this paper
• Short-term combination of glatiramer acetate with i.v. steroid treatment preceding treatment with GA alone assessed by MRI-disease activity in patients with relapsing-remitting multiple sclerosis.

  2008cited by this paper
• Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS

  2008cited by this paper
• Glatiramer acetate treatment does not modify the clinical course of (NZB x BXSB)F1 lupus murine model.

  2008cited by this paper
• Impact of Warm Compresses on Local Injection‐Site Reactions with Self‐Administered Glatiramer Acetate

  2008cited by this paper
• Exacerbation of autoimmune arthritis by copolymer-I through promoting type 1 immune response and autoantibody production

  2008cited by this paper
• Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.

  2008cited by this paper
• Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing–remitting multiple sclerosis in Argentina

  2008cited by this paper
• Neurogenesis and Neuroprotection in the CNS — Fundamental Elements in the Effect of Glatiramer Acetate on Treatment of Autoimmune Neurological Disorders

  2007cited by this paper
• Relapsing neuromyelitis optica responsive to glatiramer acetate treatment

  2007cited by this paper
• The therapeutic effect of glatiramer acetate in a murine model of inflammatory bowel disease is mediated by anti-inflammatory T-cells.

  2007cited by this paper
• Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial

  2007cited by this paper
• A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients

  2006cited by this paper
• Immunomodulatory Therapeutic Effect of Glatiramer Acetate on Several Murine Models of Inflammatory Bowel Disease

  2006cited by this paper
• The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration.

  2006cited by this paper
• Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study.

  2006cited by this paper
• Glatiramer acetate in treatment‐naïve and prior interferon‐β‐1b‐treated multiple sclerosis patients *

  2006cited by this paper
• Clinical course after change of immunomodulating therapy in relapsing–remitting multiple sclerosis

  2006cited by this paper
• Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3.

  2005cited by this paper
• The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice.

  2005cited by this paper
• Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8‐year data

  2005cited by this paper
• Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

  2005cited by this paper
• Combined treatment of glatiramer acetate and low doses of immunosuppressive drugs is effective in the prevention of graft rejection.

  2005cited by this paper
• Therapeutic Effect of the Immunomodulator Glatiramer Acetate on Trinitrobenzene Sulfonic Acid‐Induced Experimental Colitis

  2005cited by this paper
• Loss of Functional Suppression by CD4+CD25+ Regulatory T Cells in Patients with Multiple Sclerosis

  2004cited by this paper
• Lipoatrophy in Patients with Multiple Sclerosis on Glatiramer Acetate

  2004cited by this paper
• Type 2 Monocyte and Microglia Differentiation Mediated by Glatiramer Acetate Therapy in Patients with Multiple Sclerosis1

  2004cited by this paper
• Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease.

  2004cited by this paper
• Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: From pipe dreams to (therapeutic) pipelines

  2004cited by this paper
• Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy

  2003cited by this paper
• A case of relapsing neuromyelitis optica treated with glatiramer acetate

  2003cited by this paper
• Therapeutic vaccine for acute and chronic motor neuron diseases: Implications for amyotrophic lateral sclerosis

  2003cited by this paper
• Glatiramer Acetate (Copolymer-1, Copaxone) Promotes Th2 Cell Development and Increased IL-10 Production Through Modulation of Dendritic Cells1

  2003cited by this paper
• Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial

  2003cited by this paper
• Copaxone’s effect on MRI-monitored disease in relapsing MS is reproducible and sustained

  2002cited by this paper
• Polyreactive antibodies to glatiramer acetate promote myelin repair in murine model of demyelinating disease

  2002cited by this paper
• European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis

  2001cited by this paper
• Glatiramer acetate reduces the proportion of new MS lesions evolving into “black holes”

  2001cited by this paper
• Copolymer 1 inhibits manifestations of graft rejection.

  2001cited by this paper
• Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone.

  2001cited by this paper
• Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: Implications for glaucoma

  2001cited by this paper
• Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis.

  2000cited by this paper
• T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies.

  2000cited by this paper
• Localized lipoatrophy after prolonged treatment with copolymer 1

  2000cited by this paper
• Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination

  2000cited by this paper
• Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells.

  2000cited by this paper
• Ibuprofen treatment versus gradual introduction of interferon β-1b in patients with MS

  1999cited by this paper
• Activated Human T Cells, B Cells, and Monocytes Produce Brain-derived Neurotrophic Factor In Vitro and in Inflammatory Brain Lesions: A Neuroprotective Role of Inflammation?

  1999cited by this paper
• Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability

  1998cited by this paper
• Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.

  1995cited by this paper
• A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis.

  1987cited by this paper
• New diagnostic criteria for multiple sclerosis: Guidelines for research protocols

  1983cited by this paper
• Suppression of experimental allergic encephalomyelitis in Rhesus monkeys by a synthetic basic copolymer.

  1974cited by this paper

• Modulating inflammation and neuroprotection in multiple sclerosis

  2018cites this paper
• Stage-Specific Immune Dysregulation in Multiple Sclerosis

  2014cites this paper